Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SymBio Pharmaceuticals's enterprise value is 円4,905 Mil.
SymBio Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円-5,780 Mil. Therefore, SymBio Pharmaceuticals's EV-to-EBITDA for today is -0.85.
The historical rank and industry rank for SymBio Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
TSE:4582'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -69.75 Med: -1.8 Max: 90.45
Current: -0.85
During the past 13 years, the highest EV-to-EBITDA of SymBio Pharmaceuticals was 90.45. The lowest was -69.75. And the median was -1.80.
TSE:4582's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs TSE:4582: -0.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SymBio Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
SymBio Pharmaceuticals's share price for today is 円63.00.
SymBio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-103.583.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's EV-to-EBITDA falls into.
SymBio Pharmaceuticals's current Enterprise Value is 円4,905 Mil.
SymBio Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-5,780 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (TSE:4582) has a EV-to-EBITDA of -0.85 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SymBio Pharmaceuticals. According to the industry distribution chart, SymBio Pharmaceuticals ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is SymBio Pharmaceuticals' EV-to-EBITDA too high?
SymBio Pharmaceuticals' current EV-to-EBITDA is -0.85. Based on the distribution chart, SymBio Pharmaceuticals ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #999999 out of 734 companies for EV-to-EBITDA. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SymBio Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current EV-to-EBITDA is -0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.49, compared to a current price of 円63.00 — trading 44.9% above its estimated fair value. The current EV-to-EBITDA is -0.85. SymBio Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current EV-to-EBITDA is -0.85 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円63.00 is trading 44.9% above its estimated GF Value™ of 円43.49.
GuruFocus considers SymBio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSE:4582:
EV-to-EBITDA: -0.85
GF Value™: 円43.49 vs. price of 円63.00 (44.9% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
31GF Score
Get the complete analysis for TSE:4582
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
